研究者業績

河合 聡人

kawai akito

基本情報

所属
藤田医科大学 医学部 医学科 講師
学位
博士(薬学)(熊本大学)

研究者番号
20435150
ORCID ID
 https://orcid.org/0000-0001-5695-8814
J-GLOBAL ID
201801011554970796
researchmap会員ID
7000023585

外部リンク

経歴

 5

論文

 22
  • Akito Kawai, Koji Nishi, Masahiro Tokuno, Masaki Otagiri, Keishi Yamasaki
    ACS Medicinal Chemistry Letters 2025年7月4日  査読有り筆頭著者責任著者
  • Chisako Iriyama, Takaya Ichikawa, Tomokazu Tamura, Mutsumi Takahata, Takashi Ishio, Makoto Ibata, Ryuji Kawai, Mitsunaga Iwata, Masahiro Suzuki, Hirokazu Adachi, Naganori Nao, Hikoyu Suzuki, Akito Kawai, Akifumi Kamiyama, Tadaki Suzuki, Yuichiro Hirata, Shun Iida, Harutaka Katano, Yasushi Ishii, Takahiro Tsuji, Yoshitaka Oda, Shinya Tanaka, Nanase Okazaki, Yuko Katayama, Shimpei Nakagawa, Tetsuya Tsukamoto, Yohei Doi, Takasuke Fukuhara, Takayuki Murata, Akihiro Tomita
    PNAS Nexus 4(4) pgaf085 2025年3月18日  査読有り
    Abstract Patients with hematologic diseases have experienced COVID-19 with prolonged, progressive course. Here we present clinical, pathological, and virological analyses of three cases of prolonged COVID-19 among patients undergoing treatment for B-cell lymphoma. These patients had all been treated with anti-CD20 antibody and bendamustine. Despite various antiviral treatments, high SARS-CoV-2 levels persisted for more than 4 weeks, and two of them succumbed to COVID-19. Autopsy showed bronchopneumonia, interstitial pneumonia, alveolar hemorrhage, and fibrosis. Overlapping CMV, fungal and/or bacterial infections were also confirmed. Sequencing of SARS-CoV-2 showed accumulation of mutations and changes in variant allele frequencies over time. NSP12 mutations V792I and M794I appeared independently in two cases as COVID-19 progressed. In vitro drug susceptibility analysis and animal experiment using recombinant SARS-CoV-2 demonstrated that each mutation, V792 and M794I, was independently responsible for remdesivir resistance and attenuated pathogenicity. E340A, E340D and F342INS mutations in the spike protein were found in one case, which may account for the sotrovimab resistance. Analysis of autopsy specimens indicated heterogeneous distribution of these mutations. In summary, we demonstrated temporal and spatial diversity in SARS-CoV-2 that evolved resistance to various antiviral agents in malignant lymphoma patients under immunodeficient conditions caused by certain types of immunochemotherapies. Strategies may be necessary to prevent acquisition of drug resistance and improve outcome, such as selection of appropriate treatment strategies for lymphoma considering patients’ immune status and institution of early intensive antiviral therapy.
  • Akito Kawai, Keishi Yamasaki, Masaki Otagiri, Yohei Doi
    Journal of Medicinal Chemistry 67(16) 14175-14183 2024年8月22日  査読有り筆頭著者責任著者
  • Akito Kawai, William C. Shropshire, Masahiro Suzuki, Jovan Borjan, Samuel L. Aitken, William C. Bachman, Christi L. McElheny, Micah M. Bhatti, Ryan K. Shields, Samuel A. Shelburne, Yohei Doi
    mBio 15(2) e02874-23 2024年2月14日  査読有り筆頭著者責任著者
  • William C Shropshire, Bradley T Endres, Jovan Borjan, Samuel L Aitken, William C Bachman, Christi L McElheny, Chin-Ting Wu, Stephanie L Egge, Ayesha Khan, William R Miller, Micah M Bhatti, Pranoti Saharasbhojane, Akito Kawai, Ryan K Shields, Samuel A Shelburne, Yohei Doi
    Journal of Antimicrobial Chemotherapy 78(10) 2442-2450 2023年8月14日  査読有り

MISC

 12

講演・口頭発表等

 34

担当経験のある科目(授業)

 6

所属学協会

 4

共同研究・競争的資金等の研究課題

 9

その他

 2
  • ①タンパク質の動的な解析 *本研究ニーズに関する産学共同研究の問い合わせは藤田医科大学産学連携推進セン ター(fuji-san@fujita-hu.ac.jp)まで
  • ①薬剤や核酸、タンパク質の構造解析(組換えタンパク質の調製からX線結晶構造解析法を用いた構造決定まで実施しています。) *本研究シーズに関する産学共同研究の問い合わせは藤田医科大学産学連携推進センター(fuji-san@fujita-hu.ac.jp)まで